Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period NORCROSS, Ga., March 06, 2017 (GLOBE NEWSWIRE) --...

PectaSol-C: Science, Inspiration and Ingenuity SANTA ROSA, Calif., June 12, 2012 (GLOBE NEWSWIRE) -- Some of the greatest rewards of science occur when revolutionary breakthroughs illuminate and advance our understanding of nature's intricacies,...

Breakthrough Research on Modified Citrus Pectin and Galectin-3 for Cardiovascular Disease, Fibrosis and Other Inflammatory Conditions SANTA ROSA, Calif., May 26, 2011 (GLOBE NEWSWIRE) -- In a new important research study out of the UK, scientists found that the specific form of Modified Citrus Pectin developed by Isaac Eliaz, M.D....